Contineum Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-60.0M | $-42.3M | $22.7M |
| Depreciation & Amortization | $323.0K | $258.0K | $195.0K |
| Depreciation | — | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $10.0M | $6.8M | $2.2M |
| Net Cash from Operating Activities | $-55.3M | $-32.8M | $19.3M |
| Investing Activities | |||
| Capital Expenditures | $231.0K | $514.0K | $414.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-3.7M | $-69.7M | $-65.6M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $112.7M | $109.0M | $56.2M |
| Net Change in Cash | $53.7M | $6.4M | $10.0M |
| Free Cash Flow | $-55.5M | $-33.4M | $18.9M |